Transient erythroblastopenia of childhood

Article written and reviewed by Dr Luca Moretti

Transient erythroblastopenia of childhood is a rare acquired hematologic syndrome characterized by a sudden and selective arrest of erythroid production in the bone marrow of a previously healthy child, resulting in normocytic, normochromic anemia and significant reticulocytopenia. It is clearly distinguished from congenital forms of erythroblastopenia by its transient nature and tendency toward spontaneous resolution.

TEC typically occurs during the first years of life, predominantly between 6 months and 4 years of age, and is the most common cause of hyporegenerative anemia in children after the first 6 months of life. Diagnosis of this condition, which is often unrecognized or confused with other forms of anemia, is crucial for appropriate clinical management and for avoiding inappropriate treatments. Over recent decades, a better understanding of the pathophysiologic mechanisms and natural history of the disease has established TEC as a benign, self-limiting entity with an excellent prognosis in almost all cases.

Etiology and risk factors

Transient erythroblastopenia of childhood is an acquired condition whose etiology remains partially unknown in most cases. Epidemiologic data and numerous observational studies suggest that TEC often results from a temporary arrest of erythropoiesis in response to an external event, most commonly an intercurrent viral infection. However, unlike pure red cell aplasia induced by parvovirus B19, most cases of TEC show no evidence of acute infection with this virus, suggesting possible involvement of other viral agents or immune mechanisms that have not yet been fully clarified.

The leading etiologic hypotheses involve transient suppression of erythroid progenitors mediated by immune factors or inflammatory cytokines released during common childhood infections, including adenovirus, enterovirus, parainfluenza viruses, influenza, HHV6, and others. In some cases, the disorder develops weeks after a febrile or infectious episode without identification of a specific causative pathogen. Most cases are sporadic and no single molecular cause has been defined; however, rare familial clusters and genetic linkage in some families have been described.

No specific validated risk factors for TEC have been defined. A nonspecific viral illness may precede the disorder, but no causative agent has been consistently demonstrated; myelotoxic exposures and immunodeficiencies must instead raise suspicion for alternative diagnoses.

Distinguishing TEC from Diamond-Blackfan anemia is based mainly on age at onset, clinical and morphologic features, absence of suggestive malformations, and, above all, the transient nature of erythroid suppression with spontaneous recovery. Genetic testing is useful in uncertain cases, but the absence of an identifiable pathogenic variant does not exclude Diamond-Blackfan anemia.

Pathogenesis and pathophysiology

The pathogenesis of transient erythroblastopenia of childhood represents a paradigmatic model of acute erythroblastic arrest, characterized by selective, functional, and transient suppression of the erythroid lineage in the bone marrow of previously healthy children. This process differs clearly from both congenital erythroblastopenias and aplasias secondary to drugs or toxic agents because it is completely reversible and causes no permanent damage to hematopoietic stem cells.

A recent infection is reported in some cases, but no specific viral agent has been consistently associated with TEC. The etiology remains undefined and any postinfectious relationship is a hypothesis, distinct from parvovirus B19 associated PRCA.

The pathogenic mechanism of TEC has not been defined. Transient immune mediated suppression of erythropoiesis, sometimes following an infection, has been proposed, but no specific dominant cytokine cascade or intracellular pathway has been demonstrated.

Experimental observations in small groups of patients have suggested serum factors or immune mediated mechanisms capable of temporarily inhibiting erythropoiesis. These findings, however, do not identify a single, consistent, or necessary mechanism for TEC.

When examined, the bone marrow typically shows reduced erythroid precursors with relative preservation of the other lineages. Bone marrow examination is unnecessary in typical cases and cannot, by itself, “exclude every” dysplastic or neoplastic process. The complete blood count shows normocytic anemia with reticulocytopenia; transient neutrophil or platelet abnormalities may occur.

The pathophysiology of TEC is characterized by the absence of structural lesions and by reversibility of the impairment. Recovery of erythropoiesis usually occurs within 4 to 8 weeks, rarely up to 3 to 4 months, with reappearance of reticulocytes and progressive normalization of hematologic values. Recurrences are exceptional, and no predisposition to chronic sequelae or clonal or myelodysplastic evolution is recognized because the stem cell population remains intact. In this sense, TEC represents a form of “functional arrest” of erythroid maturation that resolves simply with time and without specific therapeutic intervention, except in cases of severe symptomatic anemia.

These pathogenic mechanisms, together with the predominantly sporadic nature of the condition and the absence of a defined persistent molecular cause in most cases, make TEC a self-limiting and benign disorder that differs profoundly from congenital forms of erythroid failure and from aplasias associated with drugs, toxins, or clonal disorders.

Clinical presentation

The clinical onset of transient erythroblastopenia of childhood is generally subacute and is often unrecognized in the initial stages, particularly in young children in whom symptoms may be subtle. The typical age range is between 6 months and 4 years, with peak incidence around 18 to 26 months. The child is usually in good general health until a few weeks before diagnosis, when parents begin to notice progressive cutaneous and mucosal pallor, fatigue, poor appetite, and reduced vitality compared with usual.

Symptoms related to hyporegenerative anemia include reduced exercise tolerance, tachycardia, mild dyspnea, or fatigue during play or feeding. In more severe cases, reduced oxygen carrying capacity may cause drowsiness, irritability, or, rarely, symptoms of high output heart failure, including tachypnea, profuse sweating, and mild hepatomegaly. Jaundice and signs of hemolysis are absent, as are, as a rule, bleeding manifestations or recurrent infections; transient neutrophil or platelet abnormalities may nevertheless occur.

The medical history often reveals a minor febrile or respiratory infection occurring a few weeks to one month before the onset of anemic symptoms. In most cases, however, the association with infection remains only suspected and cannot always be established with certainty.

On physical examination, the most common findings are marked pallor, tachycardia, and, in severe anemia, functional systolic murmurs caused by increased blood flow across the cardiac valves. Hepatosplenomegaly, lymphadenopathy, and signs of bone marrow infiltration are absent, findings that help exclude more serious causes of pediatric anemia such as hematologic malignancies or generalized bone marrow failure syndromes.

The presence of congenital malformations or dysmorphic features is atypical and must always raise suspicion for alternative diagnoses, particularly congenital erythroblastopenias such as Diamond-Blackfan anemia.

The severity of the clinical presentation can vary considerably: in most cases anemia is moderate, well tolerated, and asymptomatic, but in a minority of patients hemoglobin may fall below 6 to 7 g/dL, requiring closer evaluation and, sometimes, temporary transfusion support.

The course of the disease is typically monophasic and self-limiting: in almost all cases, symptoms regress spontaneously within a few weeks, with progressive hematologic improvement and disappearance of symptoms without sequelae, while recurrences are exceptional.

Diagnostic evaluation and diagnosis

Diagnosis of transient erythroblastopenia of childhood is based on a rigorous and progressive clinical and diagnostic workup whose primary objective is to distinguish TEC from other forms of hyporegenerative anemia, especially congenital erythroblastopenias and more severe bone marrow failure disorders. Diagnostic suspicion typically arises from the combination of a subacute clinical presentation in a previously healthy child, normocytic, normochromic anemia of variable severity, and marked reticulocytopenia in the absence of signs of hemolysis, recurrent infections, or systemic symptoms.

The first step is a complete blood count, which documents reduced hemoglobin with a mean corpuscular volume (MCV) normal for age, associated with a markedly reduced reticulocyte count (reticulocytopenia). The other cell lines, leukocytes and platelets, are often normal, although transient neutropenia or platelet abnormalities may occur. The peripheral blood smear shows morphologically normal erythrocytes without significant anisopoikilocytosis or signs of hemolysis, such as schistocytes or spherocytes, or dysplasia.

When TEC is suspected, the differential diagnosis primarily includes Diamond-Blackfan anemia, pure red cell aplasia caused by parvovirus B19, pediatric myelodysplastic syndromes, and severe nutritional deficiency anemias. A detailed history must investigate a history of recent infections, the absence of congenital malformations, lack of a family history of hematologic diseases, and completely normal previous physical and neurodevelopmental development.

Additional investigations include hemolysis parameters, which in typical TEC do not indicate a hemolytic process, and vitamin B12 or folate when the clinical context suggests deficiency. Infectious disease testing should be reserved for specific clinical indications and does not routinely confirm TEC.

The decisive examination, reserved for cases with persistent diagnostic uncertainty or atypical clinical presentations, is bone marrow evaluation. Bone marrow aspiration and, if necessary, bone marrow biopsy demonstrate overall normocellularity with drastic depletion of erythroid precursors, in the absence of dysplastic abnormalities, neoplastic infiltrates, or fibrosis. The granulocytic and megakaryocytic lineages appear intact.

It is essential to exclude the diagnostic features of congenital erythroblastopenias, particularly Diamond-Blackfan anemia, which are characterized by earlier onset, persistent macrocytosis, associated malformations, and a possible family history. In uncertain cases, genetic evaluation of genes associated with Diamond-Blackfan syndrome is indicated, while recognizing that a negative result does not exclude it. The absence of congenital features, together with the typical spontaneous resolution, supports the diagnosis of TEC.

The definitive diagnosis of transient erythroblastopenia of childhood is therefore based on three key elements:

• Acute or subacute onset of hyporegenerative anemia with reticulocytopenia in a previously healthy child.
• Absence of persistent or progressive cytopenias, congenital malformations, or a family history suggestive of inherited syndromes.
• Bone marrow findings, when evaluated, of selective depletion of the erythroid lineage in normocellular marrow, with spontaneous recovery of erythropoietic function within weeks or a few months.

Timely recognition of this entity makes it possible to avoid unnecessary invasive treatments, reassure the family regarding the benign prognosis, and establish appropriate follow-up focused solely on monitoring the complete blood count and spontaneous recovery of erythroid function.

Treatment and prognosis

Treatment of transient erythroblastopenia of childhood is based on conservative management, given the self-limiting and benign nature of the condition in almost all cases. The main objective is to provide adequate clinical support during the phase of erythroid suppression, preventing complications of severe anemia while limiting invasive or unnecessary interventions.

Most children require no specific therapy: clinical monitoring and serial complete blood counts are indicated, with observation for signs of symptomatic anemia or comorbidities that could reduce tolerance of anemia.

Packed red blood cell transfusion is reserved for severe symptomatic anemia with hypoxia or cardiocirculatory compromise and should not be based on an isolated hemoglobin threshold. When needed, a single transfusion is usually sufficient; the need for repeated transfusions requires reassessment of the diagnosis.

There is no role for corticosteroids, immunosuppressants, recombinant erythropoietin, or other pharmacologic therapies: these treatments are not only ineffective in TEC but expose the patient to unjustified risks and are not supported by the pathophysiologic rationale. The only intervention truly required in the most severe cases is temporary transfusion support.

The prognosis of TEC is excellent: almost all cases show complete spontaneous resolution of anemia within 4 to 8 weeks, rarely up to 3 to 4 months. Recovery of erythropoiesis is manifested by a progressive increase in reticulocytes and normalization of hemoglobin values, with exceptional recurrences and no recognized progression to chronic forms of bone marrow failure.

Only in very rare cases, described mainly in the international literature, may TEC have a more prolonged course or greater severity, but even in these patients the long term outcome remains favorable, without an increased risk of hematologic malignancies or chronic diseases.

Follow-up is limited to clinical and laboratory surveillance until complete resolution of the hematologic abnormalities. If anemia persists beyond 4 to 6 months, symptoms recur, or other signs of bone marrow failure develop, the diagnosis must be critically reassessed with further investigations to exclude congenital or secondary forms.

Complications

Complications of transient erythroblastopenia of childhood are rare, reflecting the benign and self-limiting nature of the disease. Nevertheless, awareness of possible adverse events, particularly in cases of severe anemia, delayed diagnosis, or suboptimal management, is essential to ensure an appropriate and timely clinical approach.

During the acute phase, the relevant complication is severe symptomatic anemia, with tissue hypoxia, persistent tachycardia, or, rarely, high output heart failure.

Transfusion reactions are possible in the few patients who receive transfusions. The need for repeated transfusions, with the resulting risk of alloimmunization or iron overload, is not expected in TEC and must prompt reconsideration of the diagnosis.

Specific infectious or hemorrhagic complications are not typical; transient neutropenia or platelet abnormalities may nevertheless occur and usually resolve spontaneously. Likewise, there is no evidence of progression to myelodysplastic syndromes, chronic bone marrow failure, or other severe hematologic diseases.

Psychological or social complications related to the diagnosis of anemia and the temporary need for medical care are generally transient and resolve with the child's recovery and family reassurance regarding the favorable prognosis.

Optimal management of TEC, based on timely recognition of the disorder, appropriate clinical monitoring, and judicious use of transfusions, allows major complications to be avoided in almost all cases and results in complete recovery without sequelae.

Bibliography
1. Mejía Sang ME, Mendez M. Diagnosing Transient Erythroblastopenia of Childhood: A Review for Pediatricians. Pediatr Ann. 2024;53(1):e34–e36.
2. Labotka RJ, Maurer HS, Honig GR. Transient erythroblastopenia of childhood. Review of 17 cases, including a pair of identical twins. Am J Dis Child. 1981;135(10):937–940.
3. Koenig HM, Lightsey AL, Nelson DP, Diamond LK. Immune suppression of erythropoiesis in transient erythroblastopenia of childhood. Blood. 1979;54(3):742–746.
4. Skeppner G, Kreuger A, Elinder G. Transient erythroblastopenia of childhood: prospective study of 10 patients with special reference to viral infections. J Pediatr Hematol Oncol. 2002;24(4):294–298.
5. Segel GB, Lichtman MA. Aplastic Anemia: Acquired and Inherited. In: Kaushansky K, Prchal JT, Burns LJ, Lichtman MA, Levi M, Linch DC, eds. Williams Hematology. 10th ed. McGraw-Hill Education; 2021.
6. van den Akker M, Dror Y, Odame I. Transient erythroblastopenia of childhood is an underdiagnosed and self-limiting disease. Acta Paediatr. 2014;103(7):e288–e294.
7. Glader BE. Diagnosis and management of red cell aplasia in children. Hematol Oncol Clin North Am. 1987;1(3):431–447.
8. Alter BP. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematology Am Soc Hematol Educ Program. 2007;2007(1):29–39.
9. Greer JP, et al. Wintrobe’s Clinical Hematology. Wolters Kluwer. 14th ed. 2019.
10. Janus J, Moerschel SK. Evaluation of anemia in children. Am Fam Physician. 2010;81(12):1462-1471.